Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

6.3%

5 terminated/withdrawn out of 80 trials

Success Rate

58.3%

-28.2% vs industry average

Late-Stage Pipeline

26%

21 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

13 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

33(41.8%)

Phase 2

23(29.1%)

Phase 3

19(24.1%)

Phase 4

2(2.5%)

N/A

2(2.5%)

79Total

Phase 1(33)

Phase 2(23)

Phase 3(19)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (80)

Showing 20 of 80 trials

NCT07570823Phase 3Not Yet Recruiting

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Role: lead

NCT07040072Phase 1Recruiting

Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC

Role: collaborator

NCT07562022Phase 3Not Yet Recruiting

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Role: lead

NCT07244510Phase 2Recruiting

Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa

Role: lead

NCT07538154Phase 1Not Yet Recruiting

A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus

Role: lead

NCT07437404Phase 3Recruiting

Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.

Role: lead

NCT07388810Not ApplicableNot Yet Recruiting

Study of Ripertamab in Children With Frequent Relapses or Steroid-Dependent Nephrotic Syndrome

Role: collaborator

NCT07388602Phase 3Recruiting

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Role: lead

NCT07297329Phase 3Recruiting

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Role: lead

NCT07362459Phase 3Recruiting

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

Role: lead

NCT04644185Phase 2Terminated

The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

Role: lead

NCT06672536Phase 1Recruiting

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

Role: lead

NCT07077252Phase 1Not Yet Recruiting

Phase I/II Study of SCTB39G in Advanced Solid Tumours

Role: lead

NCT07050641Phase 1Recruiting

Phase I/II Study of SCTB39-1 in Advanced Solid Tumours

Role: lead

NCT05888870Phase 4Recruiting

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Role: collaborator

NCT06841042Phase 1Recruiting

A Study of SCTB35 in Patients with Systemic Lupus Erythematosus

Role: lead

NCT06754605Phase 1Recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

Role: lead

NCT06801509Phase 1Not Yet Recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine

Role: lead

NCT06790888Not ApplicableNot Yet Recruiting

Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure

Role: collaborator

NCT06600022Phase 1Recruiting

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.

Role: lead